CNBC host Brian Sullivan reminded Shkreli that Daraprim had initially been a $1 drug.
“When you bought this company did you buy it because you knew you could raise the price?” Sullivan asked.
“We definitely planned on raising the price, that’s for sure,” Shkreli admitted. “We’ve took it to a price where we can make a comfortable profit, but not any kind of ridiculous profit.”